ASX - By Stock
|
MSB |
Re:
CHF - The real phase 3 headlines
|
|
jazzapat
|
147 |
74K |
12 |
24/12/20 |
24/12/20 |
ASX - By Stock
|
147
|
74K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
something must be brewing
|
|
jazzapat
|
112 |
46K |
9 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
112
|
46K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Company Update - Webcast and Forward Thoughts
|
|
jazzapat
|
273 |
128K |
2 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
273
|
128K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
jazzapat
|
555 |
269K |
3 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
269K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
jazzapat
|
555 |
269K |
59 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
269K
|
59
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
jazzapat
|
635 |
279K |
6 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
279K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
jazzapat
|
635 |
279K |
15 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
279K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
10 Sept 12pm NSW Stem Cell Network - Stem Cells vs COVID19
|
|
jazzapat
|
220 |
85K |
33 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
220
|
85K
|
33
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jazzapat
|
18K |
6.9M |
10 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
18K
|
6.9M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Pick the Closing Price after FDA approval on that day
|
|
jazzapat
|
449 |
191K |
81 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
449
|
191K
|
81
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jazzapat
|
320 |
130K |
28 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
320
|
130K
|
28
|
|
ASX - By Stock
|
SPL |
Re:
Bell Potter raises target to $2.20
|
|
jazzapat
|
13 |
5.8K |
5 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
13
|
5.8K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
jazzapat
|
206 |
65K |
5 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
jazzapat
|
206 |
65K |
10 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
10
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
jazzapat
|
206 |
65K |
2 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
jazzapat
|
206 |
65K |
9 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
jazzapat
|
425 |
192K |
52 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
425
|
192K
|
52
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
1 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
95
|
31K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
2 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
95
|
31K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
4 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
95
|
31K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
4 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
95
|
31K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
6 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
95
|
31K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
jazzapat
|
95 |
31K |
3 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
95
|
31K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
ODAC voting results
|
|
jazzapat
|
80 |
27K |
5 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
80
|
27K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
BP update (Tanu) .. GLTAH
|
|
jazzapat
|
56 |
31K |
3 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
56
|
31K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
FDA ODAC Meeting Material discussion analysis
|
|
jazzapat
|
491 |
194K |
11 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
491
|
194K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
BLA 125706 Remestemcel-L FDA briefing document
|
|
jazzapat
|
41 |
22K |
3 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
41
|
22K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
BLA 125706 Remestemcel-L FDA briefing document
|
|
jazzapat
|
41 |
22K |
10 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
41
|
22K
|
10
|
|
ASX - By Stock
|
SPL |
Re:
At least 3 market sensitive announcements were in last update
|
|
jazzapat
|
20 |
7.9K |
6 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
20
|
7.9K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: DEP docetaxel and gemcitabine combination trial commences
|
|
jazzapat
|
19 |
6.0K |
7 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
19
|
6.0K
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
jazzapat
|
23K |
13M |
3 |
15/07/20 |
15/07/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Vivagel marketing
|
|
jazzapat
|
79 |
23K |
0 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
79
|
23K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: DEP lutetium effective in human prostate cancer model
|
|
jazzapat
|
35 |
11K |
2 |
17/06/20 |
17/06/20 |
ASX - By Stock
|
35
|
11K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Carol Schwartz and Jackie Fairley interview
|
|
jazzapat
|
7 |
2.5K |
1 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
7
|
2.5K
|
1
|
|
ASX - By Stock
|
NHC |
Re:
Ann: New Acland Stage 3 update
|
|
jazzapat
|
26 |
11K |
3 |
05/06/20 |
05/06/20 |
ASX - By Stock
|
26
|
11K
|
3
|
|
ASX - By Stock
|
NHC |
Re:
Interesting article
|
|
jazzapat
|
10 |
4.6K |
3 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
10
|
4.6K
|
3
|
|
ASX - By Stock
|
NHC |
Re:
Worried about New Hope
|
|
jazzapat
|
17 |
7.9K |
4 |
29/05/20 |
29/05/20 |
ASX - By Stock
|
17
|
7.9K
|
4
|
|
ASX - By Stock
|
NHC |
Re:
Worried about New Hope
|
|
jazzapat
|
17 |
7.9K |
3 |
23/05/20 |
23/05/20 |
ASX - By Stock
|
17
|
7.9K
|
3
|
|
ASX - By Stock
|
EML |
Re:
EML still worth $7+
|
|
jazzapat
|
124 |
72K |
10 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
124
|
72K
|
10
|
|
ASX - By Stock
|
SPL |
Re:
Ann: DEP irinotecan phase 2 commences after positive phase 1
|
|
jazzapat
|
41 |
13K |
10 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
41
|
13K
|
10
|
|
ASX - By Stock
|
SPL |
Re:
Ann: DEP irinotecan phase 2 commences after positive phase 1
|
|
jazzapat
|
41 |
13K |
4 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
41
|
13K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma presents at Macquarie Australia Conference
|
|
jazzapat
|
35 |
10K |
3 |
05/05/20 |
05/05/20 |
ASX - By Stock
|
35
|
10K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013 and COVID
|
|
jazzapat
|
56 |
14K |
0 |
04/05/20 |
04/05/20 |
ASX - By Stock
|
56
|
14K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013 outperformed Gilead against COVID-19
|
|
jazzapat
|
33 |
9.6K |
1 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
33
|
9.6K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
jazzapat
|
847 |
339K |
24 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
847
|
339K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
jazzapat
|
847 |
339K |
12 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
847
|
339K
|
12
|
|
ASX - By Stock
|
SPL |
Re:
The Australian Government is providing AU$13 million (US$8 million)
|
|
jazzapat
|
21 |
6.8K |
2 |
24/04/20 |
24/04/20 |
ASX - By Stock
|
21
|
6.8K
|
2
|
|
ASX - By Stock
|
NHC |
Re:
Ann: New Hope welcomes Court of Appeal decision
|
|
jazzapat
|
43 |
68K |
6 |
23/04/20 |
23/04/20 |
ASX - By Stock
|
43
|
68K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 shows significant activity against coronavirus
|
|
jazzapat
|
180 |
62K |
0 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
180
|
62K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 shows significant activity against coronavirus
|
|
jazzapat
|
180 |
62K |
1 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
180
|
62K
|
1
|
|